Section Arrow
BRVE.NASDAQ
- Braveheart Bio Inc.
Quotes are at least 15-min delayed:2026/11/07 00:03 EST
Regular Hours
Last
 18.6
+1.185 (+6.80%)
Day High 
18.99 
Prev. Close
17.415 
1-M High
22.22 
Volume 
702.05K 
Bid
16.88
Ask
21.8
Day Low
16.89 
Open
17.55 
1-M Low
16.7 
Market Cap 
1.57B 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 20.95 
20-SMA 20.44 
50-SMA 22.91 
52-W High 32 
52-W Low 16.7 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.60/--
Enterprise Value
1.57B
Balance Sheet
Book Value Per Share
-1.07
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
0
Operating Revenue Per Share
--
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
KPTIKaryopharm Therapeutics Inc.0.0549-0.0052-8.65%-- 
INOInovio Pharmaceuticals1.215-0.235-16.21%-- 
LABTLakewood-Amedex Biotherapeutics Inc0.3863-0.1543-28.54%-- 
CDTCdt Equity Inc1.31+0.464+54.85%0PE
MRNAModerna254.19+12.73+5.27%-- 
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.